New reports view cognitive dysfunction and chronic heart failure markets
The market for cognitive dysfunction - which encompasses several distinct disorders - will experience a dramatic overall sales increase, transforming the market from a meager $300.0 million in 2006 to $3.7 billion in 2016, driven by sales of new drugs from Myriad Genetics, Elan/Wyeth, Targacept/AstraZeneca and Memory Pharmaceuticals/Roche, according to research and advisory firm Decision Resources.
Four key cognitive dysfunctions are considered in the report-mild cognitive impairment, cognitive impairment associated with schizophrenia, cognitive dysfunction in multiple sclerosis and likewise the condition in traumatic brain injury.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze